Danaher Corporation $DHR Holdings Lifted by Abacus Planning Group Inc.

Abacus Planning Group Inc. boosted its position in shares of Danaher Corporation (NYSE:DHR) by 5.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 5,710 shares of the conglomerate’s stock after buying an additional 307 shares during the period. Abacus Planning Group Inc.’s holdings in Danaher were worth $1,128,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of DHR. Hills Bank & Trust Co boosted its position in shares of Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock valued at $3,693,000 after purchasing an additional 53 shares during the period. Worth Financial Advisory Group LLC boosted its position in shares of Danaher by 4.6% in the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares during the period. Sageworth Trust Co boosted its position in shares of Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock valued at $493,000 after purchasing an additional 54 shares during the period. 1834 Investment Advisors Co. boosted its position in shares of Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 54 shares during the period. Finally, Bruce G. Allen Investments LLC boosted its position in shares of Danaher by 13.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after purchasing an additional 54 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by company insiders.

Danaher Stock Down 1.1%

DHR opened at $210.64 on Friday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.41. The business has a 50-day moving average of $200.00 and a 200-day moving average of $197.40. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a market capitalization of $150.83 billion, a PE ratio of 44.82, a price-to-earnings-growth ratio of 3.03 and a beta of 0.77.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the business earned $1.72 EPS. The business’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 27.23%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Guggenheim reiterated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Bank of America decreased their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Wells Fargo & Company decreased their price objective on Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Finally, Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.91.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.